Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Colorectal Neoplasms

  Free Subscription

Articles published in Oncogene

Retrieve available abstracts of 55 articles:
HTML format

Single Articles

    October 2021
  1. ZHANG J, Zhai J, Wong CC, Chen H, et al
    A novel amplification gene PCI domain containing 2 (PCID2) promotes colorectal cancer through directly degrading a tumor suppressor promyelocytic leukemia (PML).
    Oncogene. 2021 Oct 8. pii: 10.1038/s41388-021-01941.
    PubMed     Abstract available

  2. GAO S, Soares F, Wang S, Wong CC, et al
    CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer.
    Oncogene. 2021 Oct 7. pii: 10.1038/s41388-021-01882.
    PubMed     Abstract available

  3. ZHENG D, Cao M, Zuo S, Xia X, et al
    RANBP1 promotes colorectal cancer progression by regulating pre-miRNA nuclear export via a positive feedback loop with YAP.
    Oncogene. 2021 Oct 6. pii: 10.1038/s41388-021-02036.
    PubMed     Abstract available

  4. TONG J, Tan X, Risnik D, Gao M, et al
    BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade.
    Oncogene. 2021 Oct 6. pii: 10.1038/s41388-021-02041.
    PubMed     Abstract available

  5. HUA Q, Zhang B, Xu G, Wang L, et al
    CEMIP, a novel adaptor protein of OGT, promotes colorectal cancer metastasis through glutamine metabolic reprogramming via reciprocal regulation of beta-catenin.
    Oncogene. 2021 Oct 4. pii: 10.1038/s41388-021-02023.
    PubMed     Abstract available

    September 2021
  6. ZHANG W, Pan R, Lu M, Zhang Q, et al
    Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin beta3/SRC pathway.
    Oncogene. 2021 Sep 29. pii: 10.1038/s41388-021-02029.
    PubMed     Abstract available

    August 2021
  7. YANG G, Huang L, Jia H, Aikemu B, et al
    NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer.
    Oncogene. 2021 Aug 12. pii: 10.1038/s41388-021-01962.
    PubMed     Abstract available

  8. CEN B, Wei J, Wang D, Xiong Y, et al
    Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer.
    Oncogene. 2021 Aug 12. pii: 10.1038/s41388-021-01972.
    PubMed     Abstract available

  9. GUO W, Zhang C, Feng P, Li M, et al
    M6A methylation of DEGS2, a key ceramide-synthesizing enzyme, is involved in colorectal cancer progression through ceramide synthesis.
    Oncogene. 2021 Aug 6. pii: 10.1038/s41388-021-01987.
    PubMed     Abstract available

  10. QIAO S, Lu W, Glorieux C, Li J, et al
    Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.
    Oncogene. 2021 Aug 4. pii: 10.1038/s41388-021-01968.
    PubMed     Abstract available

  11. ZHANG J, Jiang X, Yin J, Dou S, et al
    RNF141 interacts with KRAS to promote colorectal cancer progression.
    Oncogene. 2021 Aug 3. pii: 10.1038/s41388-021-01877.
    PubMed     Abstract available

    July 2021
  12. CABOT D, Brun S, Paco N, Ginesta MM, et al
    KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer.
    Oncogene. 2021 Jul 31. pii: 10.1038/s41388-021-01967.
    PubMed     Abstract available

  13. FAN X, Wang Y, Jiang T, Liu T, et al
    B-Myb accelerates colorectal cancer progression through reciprocal feed-forward transactivation of E2F2.
    Oncogene. 2021 Jul 27. pii: 10.1038/s41388-021-01961.
    PubMed     Abstract available

  14. KOBELT D, Perez-Hernandez D, Fleuter C, Dahlmann M, et al
    The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis.
    Oncogene. 2021 Jul 10. pii: 10.1038/s41388-021-01917.
    PubMed     Abstract available

  15. RUAN DY, Li T, Wang YN, Meng Q, et al
    FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis.
    Oncogene. 2021 Jul 3. pii: 10.1038/s41388-021-01916.
    PubMed     Abstract available

    June 2021
  16. SUN L, Patai AV, Hogenson TL, Fernandez-Zapico ME, et al
    Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer.
    Oncogene. 2021 Jun 30. pii: 10.1038/s41388-021-01910.
    PubMed     Abstract available

  17. ZHAO S, Guan B, Mi Y, Shi D, et al
    LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit.
    Oncogene. 2021 Jun 18. pii: 10.1038/s41388-021-01859.
    PubMed     Abstract available

  18. WANG H, Wang X, Zhang H, Deng T, et al
    The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer.
    Oncogene. 2021 Jun 17. pii: 10.1038/s41388-021-01898.
    PubMed     Abstract available

  19. MCANDREWS KM, Vazquez-Arreguin K, Kwak C, Sugimoto H, et al
    alphaSMA(+) fibroblasts suppress Lgr5(+) cancer stem cells and restrain colorectal cancer progression.
    Oncogene. 2021 Jun 9. pii: 10.1038/s41388-021-01866.
    PubMed     Abstract available

  20. MALKOMES P, Lunger I, Oppermann E, Abou-El-Ardat K, et al
    Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53.
    Oncogene. 2021 Jun 8. pii: 10.1038/s41388-021-01847.
    PubMed     Abstract available

    May 2021
  21. YOU J, Li J, Ke C, Xiao Y, et al
    Oncogenic long intervening noncoding RNA Linc00284 promotes c-Met expression by sponging miR-27a in colorectal cancer.
    Oncogene. 2021 May 28. pii: 10.1038/s41388-021-01839.
    PubMed     Abstract available

  22. CHEN J, Na R, Xiao C, Wang X, et al
    The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy.
    Oncogene. 2021 May 14. pii: 10.1038/s41388-021-01815.
    PubMed     Abstract available

  23. ZHANG XL, Hu LP, Yang Q, Qin WT, et al
    CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-beta receptors in colorectal cancer.
    Oncogene. 2021 May 13. pii: 10.1038/s41388-021-01827.
    PubMed     Abstract available

  24. ZENG K, Chen X, Hu X, Liu X, et al
    Correction: LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation.
    Oncogene. 2021 May 6. pii: 10.1038/s41388-021-01795.

    April 2021
  25. LIU J, Huang Z, Chen HN, Qin S, et al
    ZNF37A promotes tumor metastasis through transcriptional control of THSD4/TGF-beta axis in colorectal cancer.
    Oncogene. 2021 Apr 19. pii: 10.1038/s41388-021-01713.
    PubMed     Abstract available

  26. XIAO Q, Gan Y, Li Y, Fan L, et al
    MEF2A transcriptionally upregulates the expression of ZEB2 and CTNNB1 in colorectal cancer to promote tumor progression.
    Oncogene. 2021 Apr 16. pii: 10.1038/s41388-021-01774.
    PubMed     Abstract available

    March 2021
  27. CHUEH AC, Advani G, Foroutan M, Smith J, et al
    CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation.
    Oncogene. 2021 Mar 25. pii: 10.1038/s41388-021-01755.
    PubMed     Abstract available

  28. WESTENDORP F, Karpus ON, Koelink PJ, Vermeulen JLM, et al
    Epithelium-derived Indian Hedgehog restricts stromal expression of ErbB family members that drive colonic tumor cell proliferation.
    Oncogene. 2021;40:1628-1643.
    PubMed     Abstract available

  29. GOLLAVILLI PN, Parma B, Siddiqui A, Yang H, et al
    The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter.
    Oncogene. 2021;40:2309-2322.
    PubMed     Abstract available

  30. FLETCHER R, Tong J, Risnik D, Leibowitz BJ, et al
    Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis.
    Oncogene. 2021;40:2035-2050.
    PubMed     Abstract available

    February 2021
  31. CUI K, Yao S, Zhang H, Zhou M, et al
    Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer.
    Oncogene. 2021 Feb 24. pii: 10.1038/s41388-021-01677.
    PubMed     Abstract available

  32. PENG K, Zhuo M, Li M, Chen Q, et al
    Correction to: Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression.
    Oncogene. 2021 Feb 22. pii: 10.1038/s41388-021-01678.

  33. XU H, Liu L, Li W, Zou D, et al
    Correction: Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01651.

    January 2021
  34. YIN XK, Wang YL, Wang F, Feng WX, et al
    PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01617.
    PubMed     Abstract available

  35. LI H, Zhao L, Lau YS, Zhang C, et al
    Genome-wide CRISPR screen identifies LGALS2 as an oxidative stress-responsive gene with an inhibitory function on colon tumor growth.
    Oncogene. 2021;40:177-188.
    PubMed     Abstract available

  36. GIRONDEL C, Levesque K, Langlois MJ, Pasquin S, et al
    Loss of interleukin-17 receptor D promotes chronic inflammation-associated tumorigenesis.
    Oncogene. 2021;40:452-464.
    PubMed     Abstract available

  37. SCHMIDT AK, Pudelko K, Boekenkamp JE, Berger K, et al
    The p53/p73 - p21(CIP1) tumor suppressor axis guards against chromosomal instability by restraining CDK1 in human cancer cells.
    Oncogene. 2021;40:436-451.
    PubMed     Abstract available

  38. BALA P, Singh AK, Kavadipula P, Kotapalli V, et al
    Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer.
    Oncogene. 2021;40:863-874.
    PubMed     Abstract available

    December 2020
  39. XU H, Liu L, Li W, Zou D, et al
    Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications.
    Oncogene. 2020 Dec 15. pii: 10.1038/s41388-020-01587.
    PubMed     Abstract available

  40. BERGIN CJ, Zouggar A, Haebe JR, Masibag AN, et al
    G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer.
    Oncogene. 2020 Dec 15. pii: 10.1038/s41388-020-01591.
    PubMed     Abstract available

  41. SHI C, Yang EJ, Liu Y, Mou PK, et al
    Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
    Oncogene. 2020 Dec 8. pii: 10.1038/s41388-020-01580.
    PubMed     Abstract available

    November 2020
  42. BECK M, Baranger M, Moufok-Sadoun A, Bersuder E, et al
    The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms.
    Oncogene. 2020 Nov 13. pii: 10.1038/s41388-020-01546.
    PubMed     Abstract available

  43. XU L, Huan L, Guo T, Wu Y, et al
    LncRNA SNHG11 facilitates tumor metastasis by interacting with and stabilizing HIF-1alpha.
    Oncogene. 2020;39:7005-7018.
    PubMed     Abstract available

    September 2020
  44. PENG K, Zhuo M, Li M, Chen Q, et al
    Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01483.
    PubMed     Abstract available

  45. GAN T, Stevens AT, Xiong X, Wen YA, et al
    Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer.
    Oncogene. 2020 Sep 24. pii: 10.1038/s41388-020-01472.
    PubMed     Abstract available

  46. JIN G, Yan M, Liu K, Yao K, et al
    Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer.
    Oncogene. 2020 Sep 22. pii: 10.1038/s41388-020-01467.
    PubMed     Abstract available

  47. REISCHMANN N, Andrieux G, Griffin R, Reinheckel T, et al
    BRAF(V600E) drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation.
    Oncogene. 2020;39:6053-6070.
    PubMed     Abstract available

    August 2020
  48. BRAGGIO D, Zewdu A, Londhe P, Yu P, et al
    beta-catenin S45F mutation results in apoptotic resistance.
    Oncogene. 2020;39:5589-5600.
    PubMed     Abstract available

    May 2020
  49. PARK SM, Hwang CY, Choi J, Joung CY, et al
    Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy.
    Oncogene. 2020;39:3803-3820.
    PubMed     Abstract available

  50. YU L, Dong L, Li H, Liu Z, et al
    Ubiquitination-mediated degradation of SIRT1 by SMURF2 suppresses CRC cell proliferation and tumorigenesis.
    Oncogene. 2020;39:4450-4464.
    PubMed     Abstract available

    April 2020
  51. LI S, Lavrijsen M, Bakker A, Magierowski M, et al
    Commonly observed RNF43 mutations retain functionality in attenuating Wnt/beta-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers.
    Oncogene. 2020;39:3458-3472.
    PubMed     Abstract available

  52. ZHUO M, Chen W, Shang S, Guo P, et al
    Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
    Oncogene. 2020;39:3336-3353.
    PubMed     Abstract available

  53. KATO H, Asamitsu K, Sun W, Kitajima S, et al
    Cancer-derived UTX TPR mutations G137V and D336G impair interaction with MLL3/4 complexes and affect UTX subcellular localization.
    Oncogene. 2020;39:3322-3335.
    PubMed     Abstract available

    March 2020
  54. LI L, Liu J, Xue H, Li C, et al
    A TGF-beta-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis.
    Oncogene. 2020;39:2125-2139.
    PubMed     Abstract available

    February 2020
  55. WANG X, Wang Y, Li L, Xue X, et al
    A lncRNA coordinates with Ezh2 to inhibit HIF-1alpha transcription and suppress cancer cell adaption to hypoxia.
    Oncogene. 2020;39:1860-1874.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.